Thank you for subscribing.

Please check your email to confirm.

Unsubscribe success..

You already subscribed and confirmed.

Please check your email.

You already subscribed.

Please check your email to confirm.

Taimei Technology Closes Series E Round Funding of USD 80 Million
Taimei Technology Closes Series E Round Funding of USD 80 Million
Taimei Tech's CEO ZHAO Lu was giving a speech. PHOTO: Credit to Taimei Tech
Associated Company
EqualOcean EqualOcean

Jan 25, 2019/EqualOcean-Taimei Technology (太美医疗) announced it completed series E round funding of USD 80 million backed by Tiger Global Management, Softbank China and Cowin Venture (凯风创投). Its existing investors include Matrix Partners China, Northern Light Venture Capital and Morningside Venture Capital.

Founded in 2013, the company is a Chinese cloud-based software provider that serves pharmaceutical companies and clinical research organizations.

The company's products are designed to enhance operational efficiency, data collection and analysis in medicine clinical trials.

Taimei has developed six types of products including Clinical Data Solutions, Imaging Solutions, Trial Management Solutions, Pharmacovigilance Services, Institutes Solutions and Drug Logistics Solutions, which covers all the pain point in biomedicine R & D process.

As a provider of cloud solutions in the life sciences field, Taimei have independently developed AIMS (Clinical Trial Management System, CTMS), eCollect (Electronic Data Capture System, EDC) , eBalance (IWRS), eReport (ePRO), eArchives (Electronic Trial Master File System, eTMF), eSafety (pharmacovigilance system, PV), eCollege (Training management system, TMS) and other core products, according to its official site.

Taimei Technology has entered into business relations with more than 200 local and global pharmaceutical companies, been initially certified with ISO 9001, ISO 27001, ISO 20000 and other quality standards, and become a member of CDISC strategy suppliers and a certified supplier of WHO-UMC (World Health Organization Uppsala Monitoring Center).

Digital energy is an urgent need for seamless medicine R & D services. Producers, medicine servers represented by CRO (Contract Research Organization), medical machines companies, researchers, hospitals, patients and regulation system are all essential for biomedicine R & D. TMCloud aims to connect different and multiple processes in the whole supply chain, especially in clinical trials and pharmacovigilance services.

More than 50 pharmaceutical and CRO companies use Taimei’s product, in which there are 10 Global 500 pharmaceutical companies. Total product amount reached 500 units, serving north of 100,000 patients.

Enterprise Information

EqualOcean is a leading industry tech media and an investment research company.
CATEGORIES: AI, Research
Last Funding Type
Series C
Number of Employees
200
Number of Funding Rounds
6
Total Funding Amount
26.79M

Enterprise Information

EqualOcean
EqualOcean is a leading industry tech media and an investment research company.
CATEGORIES: AI, Research
Last Funding Type
Series C
Number of Employees
200
Number of Funding Rounds
6
Total Funding Amount
26.79M

Reach the Author!

Ask the author questions about the copied text

MOST READ

THE LATEST

Any Question

EqualOcean is a leading industrial tech media and investment research company that focuses on technological and industrial innovation in China.

We aim to assist Chinese entrepreneurial enterprises to break into the global market and provide overseas investors, VCs, and enterprises with a deeper understanding of China's business environment and to seize opportunities in China.

Join over 800,000 of your peers